What is Cerevance?
Cerevance operates at the intersection of advanced data science and clinical neurology. The company utilizes its proprietary NETSseq technology platform to identify transcriptional and epigenetic variations across specific cell types in human brains. By analyzing samples spanning nine decades of human life, Cerevance is building a comprehensive atlas of brain health and disease. This data-driven methodology allows the firm to pinpoint novel therapeutic targets for neurodegenerative conditions, positioning it as a high-value player in the global pharmaceutical landscape. Headquartered in Boston, the company leverages deep biological insights to address significant unmet needs in brain disease treatment.
How much funding has Cerevance raised?
Cerevance has raised a total of $204.5M across 4 funding rounds:
Series A
$21.5M
Series B
$116M
Other Financing Round
$47M
Series C
$20M
Series A (2016): $21.5M with participation from Takeda Pharmaceutical Company and Lightstone Ventures launched
Series B (2023): $116M led by Dolby Family Ventures, Takeda Pharmaceutical Company, UPMC, Foresite Capital, Dementia Discovery Fund, Lightstone Ventures, Casdin Capital, GV, and Bill Gates
Other Financing Round (2024): $47M supported by Agent Capital
Series C (2026): $20M featuring GV, Gates Frontier, Double Point Ventures, and Lightstone Ventures
Key Investors in Cerevance
Takeda Pharmaceutical Company
Founded in 1781, Takeda is a global research-driven pharmaceutical leader with a deep focus on neuroscience, oncology, and rare diseases.
GV
GV is a prominent venture capital firm that provides financial backing to high-growth startups across the life sciences and frontier technology sectors.
Lightstone Ventures
Lightstone Ventures specializes in partnering with biotech and medtech leaders to transform cutting-edge laboratory science into viable patient therapies.
What's next for Cerevance?
With the recent influx of $20M, Cerevance is well-positioned to transition its lead candidates through advanced clinical trials. The strategic focus will likely remain on scaling the NETSseq platform to broaden the scope of its therapeutic discovery, potentially expanding into new neurological indications. As the company matures, the emphasis will shift toward establishing commercial partnerships and validating its pipeline in human clinical settings. Investors are closely monitoring the firm's ability to translate its unique epigenetic insights into tangible, disease-modifying therapies that could redefine the standard of care for patients suffering from complex brain disorders.
See full Cerevance company page
